Pure Bioscience, INC 8-K filings

PURE Bioscience announced fiscal third quarter 2026 financial results, showing increased net product sales and a reduced net loss for the nine-month period, alongside a significant leadership transition.

PURE Bioscience, Inc. has secured $1.0 million in a private placement financing through the issuance of 18,131,096 shares of common stock.

PURE Bioscience, Inc. announced fiscal first quarter 2026 financial results, reporting increased net product sales and a reduced net loss.

PURE Bioscience, Inc. announced key leadership promotions, appointing Jeffrey Kitchell as President and Dolana Blount as Vice President of Operations, effective November 17, 2025.

PURE Bioscience, Inc. announced improved financial results for fiscal year 2025, driven by increased sales and reduced operating expenses, alongside strategic expansion into new markets.

PURE Bioscience, Inc. announced its fiscal third quarter 2025 financial results, showing increased net product sales and a reduced net loss for the quarter, alongside the successful demonstration of its SDC technology in commercial dairy plants.

PURE Bioscience reports a slight increase in net product sales for fiscal Q2 2025, but continues to operate at a net loss.

Pure Bioscience successfully held its Annual Meeting of Stockholders on January 22, 2025, electing directors and ratifying the appointment of its independent auditor.

PURE Bioscience reported a decrease in net product sales for the fiscal first quarter of 2025, primarily due to a large customer's budgetary constraints.

PURE Bioscience announced its fiscal year 2024 financial results, highlighting a shift to a distribution-focused business model and a reduction in net loss.

Pure Bioscience, Inc. has entered into a Note Purchase Agreement, securing an initial $500,000 in convertible promissory notes with the possibility of raising up to $3 million.

Pure Bioscience has increased its authorized common stock shares from 150 million to 200 million following shareholder approval at the 2024 annual meeting.

PURE Bioscience announced its fiscal third quarter 2024 financial results, highlighting a shift towards a distributor-focused business model and increased social media engagement.

Pure Bioscience has appointed Darin Zehr, a seasoned food industry professional, to its Board of Directors, effective May 1, 2024.

Pure Bioscience, Inc. has entered into a Note Purchase Agreement, securing an initial $500,000 in convertible promissory notes with a potential total offering of $3 million.

PURE Bioscience reported a decrease in second-quarter revenue due to an unexpected interruption with a major customer, though six-month results showed overall improvement.

Pure Bioscience held its annual meeting on February 21, 2024, where shareholders elected directors, ratified auditors, approved executive compensation, adopted an equity incentive plan, and approved an increase in authorized shares.